Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 19Dermatologic 7Plasma cell 4Other hematologic neoplasm 4Myeloid 4Lymphoid 4Breast 4Sarcoma 2Gynecologic 2Thoracic 1Classical hematology 1

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Breast Neoplasms 5Melanoma 4Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Vaginal Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Stomach Neoplasms 2Penile Neoplasms 2Papillomavirus Infections 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Mesothelioma 1

Interventions

pembrolizumab 10Filgrastim 7Ifosfamide 4Carboplatin 4aldesleukin 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Counseling 3fludarabine phosphate 2fludarabine 2etoposide phosphate 2cemiplimab 2belinostat 2atezolizumab 2Thiotepa 2Surveys and Questionnaires 2Radiotherapy 2Nivolumab 2Methods 2Metformin 2Early Intervention, Educational 2Doxorubicin 2Bupropion 2Blood Specimen Collection 2Amifostine 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × fludarabine phosphate × Gynecologic × Clear all
NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 22 charts
BreastDermatologicGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡